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Abstract: The paper presents the results of a rabbit blood biochemical study after the substitution of simulated defects in spongy and
compact bone tissue by platelet-rich fibrin and its combination with hydroxyapatite granules with β-tricalcium phosphate. The aim of
the work is to establish the biochemical features of reparative osteogenesis in the time of osteosubstitution by platelet-enriched fibrin
and its combination with hydroxyapatite and β-tricalcium phosphate. Bone defects (d = 3 mm) were modeled in rabbits from control
and experimental groups (n = 12) under general anaesthesia. In the control group, a replacement was performed with autologous fibrin
enriched with platelets (PRF), and in the experimental group, it was combined with hydroxyapatite ceramics. Content of biochemical
substances was determined: soluble fibrin, the activity of antithrombin-III in blood plasma, nitric oxide (NO), haptoglobin, and markers of
bone metabolism (bone isoenzyme alkaline phosphatase (BAP) and tartrate-resistant acid phosphatase (TrAP) in serum. Measurements
were performed with a spectrophotometer Stat Fax 4500. It is established that the dynamics of changes in biochemical parameters reflect
certain features of osteosubstitution by different materials. In particular, the inflammatory-resorptive stage of reparative osteogenesis in
the period up to the 7th day is characterized by an increase in blood concentrations of NO, haptoglobin, and soluble fibrin. However,
the intensity of the acute phase in the case of combined osteosubstitution is significantly lower. The next peak of NO concentration
on the 14th day indicates early angiogenesis with combined osteosubstitution. The two-phase degree of osteoresorption at the level
of TrAP is significantly lower than combined osteosubstitution, and the intensity of osteogenic processes at the level of BAP, on the
contrary, earlier. Also used biochemical parameters can be prognostic criteria for the analysis of fracture consolidation in conditions of
osteosubstitution with different materials.
Keywords: Platelets, bone markers, tartrate-resistant acid phosphatase, bone alkaline phosphatase isoenzyme

1. Introduction
Reparative osteogenesis is a cascade-complex molecularbiological and histomorphological process [1]. It is quite long
in time; therefore, it often makes it difficult to consolidate
fractures, which prompts the search for new methods and
means aimed at optimizing reparative osteogenesis [2–4].
This is topical for human medicine, veterinary traumatology,
and orthopedics, especially in dogs, horses, and exotic
animals.
Thus, among bone injuries in dogs, a fairly significant
proportion of comminuted fractures is 60%. With this type
of bone pathology, there is a high risk of dysregeneration or
loss of reparative potential [5–7]. In any case, in the area of
bone injury, hemorrhage and the formation of a hematoma
occur, the structural and functional elements of which are
the matrix for the deployment of regenerative processes
[8]. At the same time, it is fibrin, which is a component
of the hematoma, that ensures the physiological stability

of its elements and functions as the primary scaffold [9],
which is gradually infiltrated by fibroblasts and endothelial
cells with subsequent collagen synthesis, vascular network
ingrowth from the edges of the maternal bone to the center.
This is how simple fractures heal by primary intention [7].
However, during the bone fragments’ reposition and their
osteosynthesis in case of fragmental fractures, the hematoma
is destroyed and removed along with bone fragments, which
leads to a decrease in osteoregenerative potential [10–12].
To optimize the healing of fractures with significant
bone defects, a number of osteoreplacement materials with
osteoconductive and osteoinductive properties are currently
being proposed, including in companion animals [13].
Although bone autotransplants are still considered the most
optimal material for bone defects’ restoration, their use,
especially in veterinary orthopedics is limited [2] mainly
due to their insufficient volume and additional injury to the
patient [14].
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The materials offered for osteoreplacement include
bioactive ceramics, bioactive glass, and biological and
synthetic polymers. Now the most promising in this case is
calcium phosphate ceramics–hydroxyapatites, tricalcium
phosphates, and their combinations, which have [14,15]
biocompatibility, sufficient osteoconductivity, and gradual
biodegradation [13,15–21].
Induction of reparative osteogenesis occurs through
various growth factors: platelet growth factor (PDGF) [2],
transforming growth factor-beta (TGF-b) [22], fibroblast
growth factor (FGF) [23], insulin-like growth factor-1
(IGF-1) and 2 (IGF-2) [24], vascular endothelial growth
factor (VEGF) [10], epidermal growth factor (EGF) and
interleukin 8 (IL-8) [2], keratinocyte growth factor (KGF)
and connective tissue growth factor (CTGF) [25–27]. It is
these growth factors that provide the cellular type of bone
tissue’s regeneration characteristic [28].
Various materials for osteoreplacement, for the most
part, have predominantly osteoconductive properties,
which lead to their combination with components capable
of inducing and regulating the molecular biological
mechanisms of reparative osteogenesis [29,30].
At the same time, platelet-rich fibrin (PRF) is a
biomaterial that has been widely used in regenerative
medicine [31,32]. It provides both adhesive processes for
osteogenic cell migration and is a strong source of growth
factors. A significant amount of them is contained in
platelet α-granules, which, when activated [33], provide
attachment, migration, proliferation, and differentiation
of cells involved in reparative osteogenesis. Studies [34]
indicate that in the case of PRF, the release of growth factors
occurs gradually over 10 days compared with the plateletrich plasma (PRP)–first-generation PRP materials.
Previously, we [35–38] during histomorphological
monitoring of technologies for obtaining platelet masses
with fibrin established their optimal parameters to
achieve the highest concentration of platelets. We also
proved clinically, radiologically and histomorphologically
osteoinductive properties of platelet-rich autofibrin under
conditions of model fractures in rabbits.
The aim of the work is to establish the biochemical
peculiar features of reparative osteogenesis in case of
osteosubstitution by platelet-enriched fibrin and its
combinations with hydroxyapatite and β-tricalcium
phosphate.
2. Materials and methods
2.1. Experiment design
The experiment protocol was approved by the Ethics
Committee of the Bila Tserkva National Agrarian
University on the treatment of animals in scientific
research and the educational process (protocol no. 1 dated
January 23, 2019).
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The studies were carried out on clinically healthy
rabbits of the Californian breed at the age of 6 months and
bodyweight of 2.5–3 kg, which were kept in the vivarium
of the Bila Tserkva National Agrarian University, in
individual cages with combined lighting and daily cleaning
according to species needs. Rabbits had unlimited access
to water, feeding was provided with a compound feed of
the trademark “Selevana” (Kyiv region, Boryspil) at the
rate of 200 g per head per day. For this purpose, control
and experimental groups of animals were formed (n = 12).
2.2. Defect modeling
Perforated defects (d = 3 mm) were modeled with a drill
in compact bone tissue–the middle of the diaphysis of the
radius’ dorsolateral surface, and in spongy–the tibial crest
from the medial side. Anesthetic management included
acepromazine-thiopental general anesthesia and local
anesthesia with 0.5% lidocaine.
2.3. Osteoreplacement
Bone damage in the control group was filled with
autologous PRF, and in the experimental group with a
combination of autologous PRF and hydroxyapatite with
β-tricalcium phosphate (HA/β-TCP–700). Interrupted
sutures were applied to soft tissue wounds, which were
removed on the 7th day. During the entire period of the
study, rabbits were clinically observed.
2.4. Osteoreplacement materials
Implants are two-phase calcium phosphate granules HA/
β-TCP–700, consisting of 70% hydroxyapatite and 30%
β-tricalcium phosphate with a granule size of 700 μm,
synthesized at the Institute of Materials Science of the
National Academy of Sciences of Ukraine (Kyiv).
Preparation of autologous PRF (Figure 1): blood was
collected from the jugular vein using a 5 mL syringe,
which was transferred into a sterile plastic tube without
anticoagulant and centrifuged at 3000 rpm for 10 min. A
clot of fibrin enriched with platelets formed in the middle
part, blood serum was separated above and around it, and
erythrocytes were located in the lower part of the tube.
Using sterile tweezers and scissors, the erythrocyte mass
was separated from the autobio material. The required
volume of PRF was taken to fill the bone defect from the
lower part of the clot with the highest concentration of
platelets (Figure 1.А), as we previously established [38].
2.5. Biochemical studies
For biochemical examination, blood sampling was
performed from the external jugular vein of rabbits before
anesthesia, on the 3rd, 7th, 14th, 21st, and 42nd day after
modeling and replacement of defects in bone tissue.
In the blood serum, the level of NO was determined
by the Green method in Golikov’s modification [39,40].
Cadmium granules were used as a reducing agent.
In the blood plasma, the level of soluble fibrin was
determined by phosphate buffer precipitation [41]. The
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Figure 1. Scheme of obtaining fibrin enriched with platelets.

activity of antithrombin-III (AT-III) by using the kits of
LLC “Laboratory Granum” (Ukraine), expressed as a
percentage of normal.
The content of haptoglobin in the serum was
determined by reaction with rivanol kits of PJSC “Reagent”
(Ukraine).
BAP activity was determined in blood serum. The
bone isoform’s activity of alkaline phosphatase was
calculated by the difference between the activities of total
and thermostable alkaline phosphatases. The test principle
is based on the cleavage of phenyl phosphate to form
phenol. Alkaline phosphatase is able to break down the
substrate –4-nitrophenyl phosphate with the formation of
phosphate and 4-nitrophenol. The reaction was stopped
with a 30 mM solution of Trilon B in 1 M NaOH. The
released reaction product –4-nitrophenol gives a yellow
color in an alkaline medium. Its intensity is determined
spectrophotometrically at λ = 410 nm and is a measure of
alkaline phosphatase activity, expressed in units/L, where
units–the amount of μmol of 4-nitrophenol, which is
formed under the action of alkaline phosphatase for 1 min
at +37 °C and is contained in 1 L of serum. To determine
the activity of thermostable alkaline phosphatase, serum
was first aged at +56 °C for 15 min, after which the samples
were transferred to an ice bath for 5 min [42].
The level of TrAP in blood serum was determined by
sets of LLC “Laboratory Granum”. The principle of the
method is the cleavage of alpha-naphthyl phosphate into
alpha-naphthol + phosphate using as a specific agent for the
bone isoenzyme acid phosphatase tartrate. Measurements
were performed with a spectrophotometer Stat Fax 4500.
Statistical processing of the results was performed
using the program Statistica 10 (StatSoft Inc., USA,
2011). The data in the tables are presented as x ± SD (x ±
deviation). Differences between groups were determined
by ANOVA, p < 0.05 was considered significant (adjusted
for Bonferroni correction).

3. Results
On the first day following surgery, a moderate
inflammatory reaction was noted in the area of the formed
defect, manifested by slight edema and an increase in local
temperature. The functions of the limbs were not impaired.
A small amount of serous exudate was released from the
edges of the wound, which dried up and formed a crust. On
the 7th day in the animals of the control and experimental
groups, there was no swelling and soreness. The edges of
the wound were connected by connective tissue adhesions.
This was the basis for removing the sutures.
3.1. Biochemical research
Dynamic changes in the concentration of NO in the blood
were established, which had certain patterns in groups of
animals (Figure 2), which is a reflection of the intensity
of the inflammatory process in the early posttraumatic
period. During the experiment, except for the 42nd day,
the difference between the groups in terms of NO level was
significant. From days 7th to 14th, it decreased, and its next
slight increase was noted from days 21st to 42nd, which was
significantly higher (p < 0.001) than the indices of animals
in the preoperative period. In the experimental group, a
phase pattern of NO level dynamics was established with
peaks on the 3rd, 14th, and 42nd days.
When determining the concentration in the blood
plasma of soluble fibrin it was found to increase significantly
during the first 7 days (Table 1) with a subsequent dynamic
decrease. In experimental animals, on day 21st, it was 1.5
times (p ˂ 0.05) less as evidence of dynamic normalization
of the hemostasis response.
At the same time, the activity of AT-III in the plasma of
animals of both groups did not change significantly (Table
1). Its decrease on the 3rd day of the posttraumatic period
was not lower than 85%.
It was found that the content of haptoglobin in blood
serum (Table 1) reached its peak value in two stages: on
the 3rd and 14th days, which was significantly higher (p
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Figure 2. Nitric oxide’s dynamics level in rabbit serum in reparative osteogenesis.
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Table 1. Dynamics of biochemical parameters in the serum and plasma of rabbits.
Indicators

Soluble fibrin,
mg%

Haptoglobin,
g/L

Antithrombin -ІІІ,
%

Clinically healthy rabbits (n = 12)

0.14 ± 0.01

1.59 ± 0.02

95.57 ± 0.84

PRF Group (n = 4)

13.26 ± 0.74•••

2.06 ± 0.24

88.5 ± 1.70••

Group
PRF + HA/β-TCP–700 (n = 4)

12.12 ± 0.93•••

1.9 ± 0.01•••

88.13 ± 0.92•••

PRF Group (n = 4)

13.64 ± 1.35•••

1.51 ± 0.01••

96.14 ± 1.55

Group
PRF + HA/β-TCP–700 (n = 4)

14.39 ± 0.65•••

1.4 ± 0.02•••***

98.5 ± 2.07

PRF Group (n = 4)

4.67 ± 0.47•••

1.82 ± 0.01•••

96.33 ± 2.19

Group
PRF + HA/β-TCP–700 (n = 4)

5.76 ± 0.63•••

1.91 ± 0.04•••

97.3 ± 1.71

PRF Group (n = 4)

4.11 ± 0.33•••

1.4 ± 0.02•••

93.6 ± 0.81

Group
PRF + HA/β-TCP–700 (n = 4)

2.7 ± 0.44•••*

1.47 ± 0.03••

94.8 ± 1.50

PRF Group (n = 4)

2.20 ± 0.13••

0.86 ± 0.10•••

95.33 ± 0.88

Group
PRF + HA/β-TCP–700 (n = 4)

1.89 ± 0.12•••

0.78 ± 0.09•••

92.65 ± 1.45

Note: control group–the defect was replaced by PRF; experimental – PRF + HA/β-TCP–700; * – р < 0.05; ** – р <
0.01; *** – p < 0.001, compared with the control group in this period of the study; • – р < 0.05; •• – р < 0.01; ••• – p
< 0.001 compared to clinically healthy animals.

˂ 0.001) than in clinically healthy animals. A significant
difference (p ˂ 0.001) between the experimental and
control groups in terms of the haptoglobin content was
established only on the 7th day.
The serum level of the BAP (Figure 3) during all 42 days
of the study was significantly higher in both groups than in
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clinically healthy animals. Meanwhile, in the experimental
group, it turned out to be significantly higher on the 7th (p
< 0.001) and 42nd (p < 0.05) days.
The level of TrAP (Figure 4) also throughout the study
in both groups was significantly higher than in clinically
healthy rabbits. At the same time, in both cases, two phases
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Figure 3. Dynamics of alkaline phosphatase’s bone isoenzyme in reparative osteogenesis in rabbits.
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Figure 4. Dynamics of tartrate-resistant acid phosphatase in reparative osteogenesis in rabbits.

of the peak values of this bone resorption’s biochemical
marker were traced–in the period of 3–7 days and 42 days.
The activity of TrAP on the 3rd, 7th, 21st, and 42nd days in
animals of the experimental group was less than in animals
of the control group (p < 0.05).
Considering the bone isoenzyme’s dynamics (ratio)
(Figure 5) of the BAP and TrAP coefficient, it follows
that in the case of osteosubstitution with PRF + HA/βTCP–700, starting from the 7th day, the osteogenic
reaction is significantly more powerful than when using
only PRF in bone defects.
In general, the dynamics of the studied biochemical
parameters reflect certain features of osteosubstitution by
different materials.

4. Discussion
One of the priority areas in solving the problem of
restoring the reparative potential of bone tissue is generally
recognized as osteoreplacement. The need for its use arises
not only in cases of significant amounts of bone loss in
comminuted fractures but also in arthroplasty or osteoplasty
of meta-epiphyseal areas in arthrological pathology, in
systemic osteopathies or neoplasia processes in bone
tissue. Although a fairly large number of osteoreplacement
materials have now been proposed, however, questions
about the degree of their osteoconductive, osteoinductive,
and osseointegrative properties, biodegradation, and
nosological validity remain open. To a large extent, the
ability of an osteoreplacement material to restore bone
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Figure 5. Dynamics of the ratio of bone isoenzyme alkaline and tartrate-resistant acid phosphatase in
reparative osteogenesis in rabbits.

tissue depends on the presence of osteoinductive properties
in it. They are trying to be achieved by including various
compounds in the composition of composite materials or
by combining them with other biomaterials [1–4].
The use of products containing an increased
concentration of platelets in their composition can provide
osteoinduction due to components that are concentrated
in platelet α-granules: PDGF, TGF-b, FGF, IGF-1, IGF-2,
VEGF, and others [33,34,43].
In particular, in the last decade, clinical and experimental
data on the effect of PRF on the repair of various tissues
have been accumulated. However, information on the use
of calcium phosphate ceramics in combination with PRPtechnologies is quite limited. It requires further in-depth
study of PRP-technologies products’ osteoinductivity
realization in combination with calcium phosphate
materials.
Previously obtained results of macro- and
histomorphological research results [32,38,43,44] showed
that hydroxyapatite ceramics with β-tricalcium phosphate
when PRF is added, acquire pronounced osteoinductive
properties, confirmed by early osteoblastic and endothelial
reactions. The research results presented here are quite
extrapolated from histomorphological ones.
The oxygenation degree affects significantly the
production of type I collagen in the bone tissue and
contributes to the induction of angiogenesis processes, which
in turn ensures the dynamism and success of reparative
osteogenesis. NO is a free radical, an angiogenesis inducer,
produced in macrophages, neutrophils, bone marrow cells,
eosinophils, and monocytes with an inducible form of NOS
[45]. Its level in the early posttraumatic period increases,
which is more pronounced in the control group. The
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subsequent rise peaks on the 14th day in the experimental
group and on the 21st day in the control group due to its
production and due to the endothelial NOS. In this case, the
expression of interleukins and integrins by endothelial cells
occurs, which causes cell migration and differentiation and
promotes the formation of the vascular tubules’ network in
the repair zone [46,47]. Our previous work [48] and other
studies [46,47] indicate a positive effect of NO donators
on angiogenesis and microcirculation in the fracture zone
due to a moderate increase in the level of nitric oxide in
the blood and increased synthesis of tissue plasminogen
activator.
The results of the presented study indicate an earlier
increase in the NO level in the case of bone defect
substitution by PRF + HA/β-TCP–700, compared with the
independent use of PRF. This fact may indicate a faster
development of the endothelial reaction, and hence the
formation of the vasculature, reflecting an earlier initiation
of angiogenesis in the experimental group in the bone
injury area.
Haptoglobin is one of the major acute-phase proteins
in rabbits. Its role is in the evolutionarily established
antibacterial defense of the body. It may remain elevated
throughout the fracture consolidation process [49–52].
In this study, in the early period, this is due to the body’s
response to injury. Moreover, its level in the experimental
group on the 7th day was lower, which indicates a limitation
of the inflammatory-resorptive phase. In the meantime, the
next peak of the haptoglobin level on the 14th day indicates
an increase in cytokine activity associated with an increase
in endothelial reactivity.
One of the hyperactivation indicators of the blood
coagulation system is the presence of soluble fibrin in
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the circulating blood, which indicates thrombinemia.
The emergence of thrombin in the blood is not only the
activation of the cascade-coagulation process but also
the stimulation of platelets with the release and binding
of fibronectin and fibrinogen on the cell surface, which
enhance the formation of fibrin and contribute to its
organization. Along with this, the processes of thrombus
formation in the body are constantly controlled by the
system of natural anticoagulants, which includes ATIII [53,54] – serine proteinase, providing 75% of the
antithrombin potential of blood plasma. The level of ATIII activity in the range of 86%–105% is considered to
be normal [53–56]. The presented study established that
its concentration did not change significantly, but on the
3rd day it decreased slightly. This fact indicates a shift in
the hemocoagulation balance towards hypercoagulation,
which, according to [57], is a typical reaction of the
hemostasis system to surgical intervention.
Typical markers of bone metabolism are osteogenesis–
bone isoenzyme of alkaline phosphatase and
osteoresorption–tartrate-resistant acid phosphatase. They
are used to assess reparative osteogenesis [58]. Osteoclasts
provide the processes of osteoresorption, oxygen
compounds lead to the destruction of bone’s matrix
components. Its degradation products, together with TrAp,
are released into the blood and reflect the degree of bone
resorption [21,59]. In this study, a two-phase increase in
the concentration of this marker is due to the occurrence
of inflammatory-resorptive processes in the first phase.
They are more pronounced in the control group than in
the experimental group and in the second phase–with the
remodeling of bone regenerates (42nd day).
Osteogenic activity of osteoblasts in the area of the
formed defect causes the elimination of the BAP into the
bloodstream. Gradual resorption of composite material’s
granules in the experimental group is accompanied by
the formation of trabeculae of bone tissue. This in turn
causes an increase in BAP activity [21,60]. These data are
consistent with the histomorphological picture, namely the
detection of higher osteoblast density in the experimental
group, as we reported earlier [38]. In particular, the
inflammatory-resorptive stage of reparative osteogenesis
in the period up to the 7th day is characterized by an
increase in blood levels of NO, haptoglobin, and soluble
fibrin. However, the intensity of the acute phase in the
case of combined osteosubstitution is significantly lower.
The next peak of NO concentration on the 14th day
indicates earlier angiogenesis. The two-phase degree
of osteoresorption, which reflects the level of TrAp, is
significantly less than the combined osteosubstitution
in rabbits of the experimental group. At the same time,

the intensity of osteogenic processes, which reflects the
activity of the bone isoenzyme alkaline phosphatase, in
experimental rabbits is earlier.
From a clinical point of view, osteosubstitution by
calcium-phosphate ceramics limits the inflammatoryresorptive phase due to osteoconductivity, and PRF
gives it osteoinductive properties and improves its
osteointegration characteristics.
5. Conclusion
Substitution of bone defects by autologous platelet-rich
fibrin and hydroxyapatite granules with β-tricalcium
phosphate has pronounced osteoinductive properties
and greater opportunities for osteointegration. This is
evidenced by the dynamics of biochemical markers such
as nitric oxide, bone isoenzyme alkaline, and tartrateresistant acid phosphatase. The studied biochemical
parameters can be prognostic criteria and can be used to
analyze the effectiveness of fracture healing in preclinical
studies. The presented combination of hydroxyapatite
ceramics with PRF may be promising for osteosubstitution
in animals.
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